Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects

178Citations
Citations of this article
148Readers
Mendeley users who have this article in their library.

Abstract

Data from studies in animal models indicate that certain lipid metabolites, particularly diacylglycerol, ceramide, and acylcarnitine, disrupt insulin action. We evaluated the relationship between the presence of these metabolites in the liver (assessed by mass spectrometry) and hepatic insulin sensitivity (assessed using a hyperinsulinemic-euglycemic clamp with stable isotope tracer infusion) in 16 obese adults (body mass index, 48 ± 9 kg/m2). There was a negative correlation between insulin-mediated suppression of hepatic glucose production and intrahepatic diacylglycerol (r = -0.609; P =.012), but not with intrahepatic ceramide or acylcarnitine. These data indicate that intrahepatic diacylglycerol is an important mediator of hepatic insulin resistance in obese people with nonalcoholic fatty liver disease. © 2012 AGA Institute.

Cite

CITATION STYLE

APA

Magkos, F., Su, X., Bradley, D., Fabbrini, E., Conte, C., Eagon, J. C., … Klein, S. (2012). Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology, 142(7). https://doi.org/10.1053/j.gastro.2012.03.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free